Calcinosis
diseaseOn this page
Also known as calcificationcalcium deposit(s)deposit(s), calciummacrocalcificationpathologic calcificationpathologically calcified structure
Summary
Calcinosis (MONDO:0002123) is a disease and 18 clinical trials. Top therapeutic interventions include cinacalcet, atorvastatin, and calcitonin. A subtype of calcium metabolic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 18
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | calcinosis |
| Mondo ID | MONDO:0002123 |
| MeSH | D002114 |
| DOID | DOID:182 |
| ICD-11 | 1374802956 |
| NCIT | C3672 |
| SNOMED CT | 6595006 |
| UMLS | C0006663 |
| MedGen | 709 |
| Is cancer (heuristic) | no |
Also known as: calcification · calcium deposit(s) · deposit(s), calcium · macrocalcification · pathologic calcification · pathologically calcified structure
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of calcium metabolic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › calcium metabolic disease › calcinosis
Related subtypes (3): hypercalcemia disease, autosomal dominant hypocalcemia, calcium-alkali syndrome
Subtypes (3): nephrocalcinosis, calciphylaxis, familial tumoral calcinosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alfacalcidol, Calcitonin.
Clinical trials & evidence
Clinical trials
Clinical trials: 18.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00211939 | PHASE4 | COMPLETED | CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients |
| NCT00379899 | PHASE4 | COMPLETED | ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis |
| NCT05162742 | PHASE3 | ACTIVE_NOT_RECRUITING | Colchicine and Inflammation in Aortic Stenosis |
| NCT06672822 | PHASE2 | RECRUITING | Intralesional Injection of STS in Treatment of Calcinosis |
| NCT00004358 | PHASE2 | COMPLETED | Phase II Study of Calcitonin for Tumoral Calcinosis |
| NCT01572844 | PHASE2 | COMPLETED | Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis |
| NCT02663895 | PHASE2 | COMPLETED | Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis |
| NCT06155578 | PHASE1/PHASE2 | UNKNOWN | Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis |
| NCT03542695 | EARLY_PHASE1 | COMPLETED | 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy |
| NCT05828186 | Not specified | ACTIVE_NOT_RECRUITING | CRUSTAL Study in China |
| NCT06217458 | Not specified | NOT_YET_RECRUITING | The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS |
| NCT06414551 | Not specified | RECRUITING | Calcification on CTCA of a CTO and PCI Outcomes |
| NCT06669195 | Not specified | NOT_YET_RECRUITING | Intravascular Lithotripsy for Acute Stent Under-expansion in Calcified Coronary Lesions |
| NCT02062125 | Not specified | COMPLETED | Calcinosis in a Single-Center Scleroderma Population |
| NCT02419040 | Not specified | COMPLETED | Treatment of Calcific Tendinitis of the Rotator Cuff |
| NCT04698902 | Not specified | COMPLETED | Influence of Calcium Pattern on Plaque Modification Achieved With Intracoronary Lithotripsy |
| NCT04862429 | Not specified | COMPLETED | Biopsy of Calcifications Under Contrast Enhancement Guide (BoCCE) |
| NCT04960319 | Not specified | UNKNOWN | Rotablation vs Intravascular Lithotripsy in Calcified Coronary Lesions |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CINACALCET | 4 | 3 |
| ATORVASTATIN | 4 | 1 |
| CALCITONIN | 4 | 1 |
| CALCIUM ACETATE | 4 | 1 |
| COLCHICINE | 4 | 1 |
| COPPER | 4 | 1 |
| SEVELAMER | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| TREPROSTINIL | 4 | 1 |
| CHEMBL4587343 | 0 | 1 |
| CHEMBL3753202 | 0 | 1 |